Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1240 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Novartis plans to close Horsham R&D site in UK

With this move, Novartis has joined Pfizer, GlaxoSmithKline and AstraZeneca, who have recently closed their R&D units in the UK. The Horsham site has almost 950 full-time equivalent

US patent for Achillion HCV drug, related compounds

ACH-1625 is Achillion‘s phase 2 protease inhibitor to treat hepatitis C virus (HCV) infection. The new patent, entitled ‘4-amino-4-oxobutanoyl peptides as inhibitors of viral replication,’ provides a patent

Biogen Idec selects PharmaPros Dataflow Manager

PharmaPros claims that Dataflow Manager offers the ability to manage clinical trials using the most accurate and up-to-date information available, enabling trial managers to make rapid and better-informed